NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report

EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huilin, Yu, Qitao, Shi, Lina, Hou, Qinhan, Dan, Liang, Liang, Chuqiao, Hong, Xiaoyu, Zhao, Yun, Ning, Ruiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730411/
https://www.ncbi.nlm.nih.gov/pubmed/36505860
http://dx.doi.org/10.3389/fonc.2022.1054593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730411/
https://www.ncbi.nlm.nih.gov/pubmed/36505860
http://dx.doi.org/10.3389/fonc.2022.1054593

Ejemplares similares